Creative Medical taps CRO Syneos to run Type 1 diabetes cell therapy study
09 Mar 2023
Cell TherapyClinical Study
Preview
Source: FierceBiotech
Last month, Syneos launched a decentralized clinical trial site network.
Biotech Creative Medical Technology has tapped Syneos Health to run a phase 1/2 randomized trial of its cell therapy for the potential treatment of Type 1 diabetes.
Creative Medical’s candidate CELZ-201 recently received the green light from the FDA to enter a trial on its safety and efficacy, which is expected to begin by the end of the month.
The cell therapy is touted as taking a new approach to leveraging the self-renewal abilities and low antigenicity of cells taken from perinatal tissue, the Phoenix-based company said in a March 7 press release. Financial details of the partnership weren’t disclosed.
“The commencement of this first-in-country clinical trial is a milestone event for Creative Medical Technology Holdings and a reflection of our commitment to developing novel therapies with the potential to address areas of high unmet medical need,” Creative's CEO Timothy Warbington said in the release.
Last month, Syneos launched a decentralized clinical trial site network with the aim of driving "digital health technology solutions." Initially launching in the U.S. and Canada, the network will cover therapeutic areas as varied as internal and general medicine, family practice, neurology, endocrinology, pediatrics and psychiatry, to name a few.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.